Increasing incidence and growing demand for biologics to bring stable growth to the global dermatitis drugs market

calendar_today 17 January, 2023 person_outline Growth Plus Reports

According to the deep-dive market assessment study conducted by Growth+ Reports, the dermatitis drugs market was pegged at ~US$ 5.8 billion in 2021. The market is expected to witness a CAGR of ~ 14.60 % from 2022 to 2030.

The rising prevalence of dermatitis is one of the main factors boosting the global market for dermatitis medications. Additionally, the dermatitis drugs market has experienced substantial growth due to the consistent growth in the use of Interleukin-4 inhibitors such as dipilumab sold under the trade name dupixent by Sanofi and Regeneron Pharmaceuticals. Similarly, Eucrisa manufactured by Ancor Pharmaceuticals is also showing high adoption. In addition, the market is also propelling due to the high frequency of atopic dermatitis and increased research and development, leading to novel medications. However, the market is constrained by stringent government regulations.

The primary reason driving the global market expansion is the increased incidence of dermatitis, with atopic dermatitis being the most common type affecting patients. In addition, according to the NCBI (National Center of Biotechnology Information), numerous prevalence studies in both adults and children were carried out in the U.S. Three studies on the prevalence of atopic dermatitis in adults were released in 2013, 2015, and 2019. 10.2%, 7.2%, and 7.3% were stated as their respective prevalence rates. It is estimated that between 2013 and 2015, the prevalence of atopic dermatitis among adults declined. But in 2019, there was a minute increase. In all three of these studies, the research populations comprised adult patients. The data shows that the frequency of atopic dermatitis in children in the U.S. between the ages of 5 and 15 was 15%, 15.1%, and 14.5%, respectively. Therefore, the average of these prevalence rates is 14.8, and the prevalence rate in children is 24%. 

High adoption of interlukin-4-inhibitors such as dipilumab is another driver propelling the growth of the global market. Dipilumab targets both IL-4 and IL-13, signaling as one of the best biologic agents approved for both moderate and severe atopic dermatitis. Dipilumab works by inhibiting the binding of IL-4 and IL-13 to respective receptors. Dupixent also controls the hyper action of the immune system in atopic dermatitis. A strong immune system will eventually show fewer symptoms of atopic dermatitis. Another medication, Eucrisa, is a phosphodiesterase-4 inhibitor. Eucrisa can be widely used in individuals from young children to adults, and offers greater benefits.

Recent research advances have shown that oral medication is showing promising benefits in moderate to severe atopic dermatitis. According to the Mount Sinai study estimate, patients with moderate to severe atopic dermatitis (AD) responded quickly and significantly to the oral drug upadacitinib in phase 3 clinical studies. Upadacitinib is a Janus kinase inhibitor 1 (JAK 1 inhibitor) that was administered to patients. It significantly decreased all clinical disease parameters and all itch-related outcomes. The remarkable outcomes were that by week 16, most patients with moderate to severe atopic dermatitis achieved a 90% disease clearance or even a 100% disease clearance.

North America, Europea, Asia Pacific, and the Rest of the World areas make up the global dermatitis drugs market. North America has dominated the global dermatitis drugs market on the global front. The primary factor contributing to this growth is the presence of major market players in the region offering better distribution of dermatitis drugs. A substantial patient population in the region increases the demand for effective and novel medicines. The Europe dermatitis drugs market is characterized by increasing research and development expenditures and favorable reimbursement policies. As a result, countries such as the United Kingdom, France, Spain, Germany, and Italy are predicted to have reasonable growth rates throughout the forecast period. The Asia Pacific dermatitis drugs market is expected to show lucrative growth in the projected period due to the introduction of innovative therapies, strong product pipeline, and a patient increase.

Some of the prominent players operating in the global dermatitis drugs market are Bayer AG, LEO Pharma A/S, Pfizer, Inc., Sanofi SA, Mylan N.V., Allergan, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Bausch Health Companies, Inc., and Teva Pharmaceuticals Industries Ltd., among others.

This report entails a thorough quantitative analysis of the trends from 2022 to 2030. The global dermatitis drugs market has been analyzed from three perspectives: drug class, disease type, and distribution channel. Based on drug class, the global dermatitis drugs market is divided into biologics, PDE4 inhibitors, corticosteroids, and calcineurin inhibitors. According to disease type, it is classified into atopic dermatitis market and contact dermatitis market. Hospitals and aesthetic clinics are the distribution channels considered for the scope of the study.  

awards awards key differentiators

Reach Us

enquire@growthplusreports.com

Web –  www.growthplusreports.com

// // //